Answers are grounded in this paper and cite their sources.
Acquired hemophilia A is rare but fatal bleeding disorder caused by an autoantibody against factor VIII. hemophilia A is more prevalent in the elderly patients and associated with other underlying such as autoimmune disorders, malignancies, pregnancy, infection and several drugs. The pattern of acquired hemophilia A is quite different from that of congenital hemophilia A. Thus, hemophilia A should be suspected in the presence of bleeding with sudden onset, often severe, occurs spontaneously or after minor trauma, following invasive procedures or surgical interventions patients without a personal or family history of bleeding. The main goal of the treatment for hemophilia A should be the control of bleeding with the use of bypassing agents and the eradication autoantibodies with the use of immunosuppressive agents. Because the remained level of factor is not correlated with the risk of fatal bleeding, appropriate hemostatic management should be in patients with clinically significant bleeding regardless of the level of factor 8 or the inhibitor of factor VIII. Because current recommendations for acquired hemophilia A are developed mainly on the retrospectively available data, larger multicenter prospective trials should be conducted developing appropriate treatments.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: